Abstract 150P
Background
HER2/neu is overexpressed in 15% - 25% of gastric cancers. IMU-131 is a B-cell peptide vaccine composed of 3 epitopes of the extracellular domain of HER2/neu. Antibodies against IMU-131 peptides elicit antitumor activity in vitro and a phase I study demonstrated safety and immunogenicity in Her-2 +/ ++ breast cancer patients.
Methods
IMU-131 was given to patients with HER2/neu positive gastric cancer in an open-label phase 1b dose escalation trial with 14 Asian and Eastern European sites. Each patient received IMU-131 on Days 0, 14, and 35, with cisplatin and 5-fluorouracil or capecitabine every 21 days. Patients remained on study until disease progression. Ongoing patients received boosters at D98 then every 84 days.
Results
14 patients were enrolled with 10 HER2 overexpressing (7 x HER2 +++, 3 x HER2 ++ FISH positive) and 4 HER2 ++ expressing tumors. Mean age was 57 yo (range of 21 - 79) with ECOG scores of 0 or 1 in 7 patients each. There were 9 Asian and 5 Caucasian patients with 5 females and 9 males. Dose levels were 10, 30 and 50 µg with 3, 6, and 5 patients respectively. 11 patients received all 3 doses and 3 patients received only 2 doses due to disease progression. P467 and HER2 antibodies were generated at all dose levels with patients dosed at 50µg responding to the vaccine with equally high antibody levels. There were no DLTs or SAEs related to IMU-131. Of the 14 patients dosed 11 were evaluable for tumor progression at day 56 and later. Of those patients, the best response was 1 CR, 5 PR, 4 SD and 1 PD. Two patients, both dosed at 50µg IMU-131, remain on study after D266, with one patient’s tumor reduced by approximately 80% from 177mm at baseline to 37mm at D266.
Conclusions
Safety data indicate that IMU-131 is well tolerated with no significant local or systemic reactions. There were no dose-limiting toxicities observed, no significant injection site reactions and no IMU-131 related SAEs. The 50µg dose produced the most consistent P467 and HER-2 specific antibodies compared to 10 and 30µg doses with preliminary response data demonstrating 50µg of IMU-131 is associated with tumor size reduction. The 50µg dose of IMU-131 is being used in the phase 2 study.
Clinical trial identification
Identifier: NCT02795988.
Editorial acknowledgement
Legal entity responsible for the study
Imugene Ltd.
Funding
Imugene Ltd.
Disclosure
N. Ede: Full / Part-time employment: Imugene. L. Chong: Full / Part-time employment, Officer / Board of Directors: Imugene. A. Good: Full / Part-time employment: Imugene. All other authors have declared no conflicts of interest.
Resources from the same session
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract